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behavior: diabetics and those with hypertension. METHODS:
Analyses are based on a nationally representative sample from
the Medicare Current Beneﬁciary Survey (MCBS) for the years
2000–2005. MCBS is a longitudinal survey and provide detailed
information on prescription drug coverage, exercise, weight, diet,
alcohol consumption, and smoking behavior. The analysis is
restricted to non-institutionalized persons above 64 years of age
with at least 2 years of data. We pay particular attention to the
non-random nature of prescription drug coverage and the selec-
tion bias caused by it. Speciﬁcally, estimates are obtained using
longitudinal data and multivariable regression models that
control for observed characteristics and unmeasured person-
speciﬁc effects (i.e., ﬁxed effects). RESULTS: An average of 16%
of the elderly switched coverage in any two consecutive years,
providing sufﬁcient variation in prescription drug coverage to
conduct ﬁxed effects analysis. In general, we ﬁnd limited evidence
of prescription drug coverage affecting health behaviors. The
lone exception was for those in public programs, where one
speciﬁcation reﬂected that elderly in the public programs were 13
percentage points (30%) less likely to participate in physical
activity than those with no prescription drug coverage after
controlling for health status. CONCLUSIONS: Although, we did
not ﬁnd any evidence of ex ante moral hazard with employer-
sponsored and HMO coverage, those in public program altered
their behavior signiﬁcantly upon gaining prescription drug
coverage.
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OBJECTIVES: The experience of TIA patients in the UK NHS
can be quite disparate. Patients presenting to primary care are
often referred to a weekly clinic, creating a delay in access to
effective treatments for this condition. The recent EXPRESS
study by Rothwell et al. (Rothwell, Peter M., et al. Lancet.
Online 9 Oct 2007 DOI:10.1016/S0140-6736(07)61448-2)
clearly demonstrated that a greater focus on effectively managing
TIA could have a signiﬁcant impact on subsequent stroke rates.
We wanted to examine how the implementation of the care
pathway outlined in Phase 2 of the EXPRESS study could affect
rates of stroke, and to explore the ﬁnancial implications of such
a shift in care. METHODS: We developed an economic model to
estimate the costs and savings associated with setting up a rapid
assessment and treatment clinic for patients with suspected TIA,
in line with Phase 2 of the EXPRESS study. We used a local
population of 500,000 people with an assumed annual incidence
of TIA of 0.19%. Current management was based on national
clinical guidelines and common clinical practice. We included all
direct costs associated with care (medications, diagnostics and
staff), and modeled the impact of changing management over a
three-year time horizon, in line with NHS planning timeframes.
RESULTS: For an assumed population of 500,000, changing the
pathway of care for TIA management resulted in 295 future
stroke events avoided over three years. As a result, the additional
costs associated with changing the pathway of care for TIA were
greatly outweighed by the savings generated through avoiding
acute management costs associated with stroke. CONCLU-
SIONS: The model suggests that the implementation of the
changes outlined in phase 2 of the EXPRESS study is cost saving
for a local population of 500,000 with an assumed TIA rate of
0.19%.
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OBJECTIVES: The aim of this study was to collect comparable
and reliable data on the lipid lowering therapy in Slovakia during
the period 1996–2006. The special interest was paid to the trend
of the statin and ﬁbrate usages. METHODS: Data of wholesalers
(following ATC/DDD), who are legally obliged to provide this
information to the Slovak Institute for Drug Control, was used
for the analysis. The results were expressed in the numbers of the
packages, ﬁnance units (€) and deﬁned daily doses per 1000
inhabitants per day (DID). RESULTS: The collected data showed
large increases in hypolipidemic consumption from 1996 to 2006
in term of DID (in 1996 (4.18), in 2001 (16.64), in 2006 (48.80).
A signiﬁcant increase in statin consumption (in 1996 (1.97), in
2001 (9.76) and in 2006 (39.66) and slight increase in ﬁbrate
consumption (in 1996 (3.59), in 2001 (6.76) and in 2006 (7.84)
in term of DID can be seen from this analysis. From the reim-
bursement point of view, simvastatin (in 2000 was reimbursed at
the level of €0.84 per DDD, in 2006 the reimbursement level was
at €0.14), ﬂuvastatin (in 2000 was reimbursed at the level of
€0.75 per DDD, in 2006 the reimbursement level was at €0.46),
atorvastatin (in 2000 was reimbursed at the level of €0.89 per
DDD, in 2006 the reimbursement level was at €0.22). Financial
expenditures were for statins (in 1996 (€989,000), in 2001
(€17,636,000) and in 2006 (€15,458,000) and for ﬁbrates
(in 1996 (€2,743,000), in 2001 (€5,570,000) and in 2006
(€3,517,000). CONCLUSIONS: Usage of generic drugs for the
treatment of hypercholesterolemia brought about a dramatic
increase in hypolipidemic consumption and the ﬁnancial expen-
ditures for health insurance funds have remained under control.
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OBJECTIVES:Assess the usage of statins in hospital after an acute
ischemic event and identify differences across Europe.
METHODS: Consecutive patients diagnosed for Ischemic Stroke
were analyzed in 2006 and 2007 in Germany, France, Italy, Spain
and UK using the Stroke Analyzer database. This was a retrospec-
tive study. RESULTS: A total of 4930 Ischemic Stroke cases were
enrolled from July 2006 until July 2007. Data were reported from
around 300 stroke specialists, neurologists, general medicine spe-
cialists. The most common treatments administered in hospital
were: aspirin 73%, statins 55%, LMWH 48%, ACE inhibitors
46%, beta blockers 21%, clopidogrel 18%. The majority of the
2726 patients treated with statins in hospital received simvastatin
47%, atorvastatin 40% and pravastatin 8%. The most common
simvastatin ﬁrst doses used were: 40 mg (48%) and 20 mg (42%).
The atorvastatin starting doses administered were mainly 20 mg
(34%), 40 mg (27%) and 80 mg (16%) atorvastatin (Spain were
leading with 25% of atorvastatin patients receiving a start dose of
80 mg). A total of 1023 patients (21%) were already receiving a
long term treatment with a statin prior to hospital admission.
Despite the fact that 56% of all ischemic stroke patients did not
have dyslipidemia, 11%of themwere already on statins before the
stroke event. Almost 31% of patients already had a previous
stroke or TIA event and 13% had a myocardial infarction more
than 1 month before the current ischemic stroke event. Treatment
with a statinwas initiated on the same day of admission to hospital
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in 38% of ischemic stroke patients (46% in Germany vs 22% in
Spain). CONCLUSIONS: These data are showing that statins are
widely used in the acute setting with signiﬁcant differences across
Europe.
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OBJECTIVES: STEMI patients (pts) presenting <12 h since onset
of symptoms should receive reperfusion therapy, which results in
important mortality reduction. However, critical presentation
timing is not the only factor that inﬂuences treatment choice for
STEMI pts. In this study we assess the scale at which clinical
guidelines are followed in the treatment of STEMI patients
presenting within the timeframe of reperfusion therapy.
METHODS: This was a retrospective patient diary study using
the IMS Health Acute Cardiovascular Analyzer. The study was
conducted in 264 hospitals with Cath-Lab facilities in France,
Germany, Italy, Spain and UK. They treated a total of 2553
patients diagnosed with STEMI, during the period of August
2006 and April 2007, with a mean of 10 patients per hospital.
Hospitals were selected to be representative by geographic
regions, size and facilities in each country. We analysed the data
to determine factors associated with patients not receiving rep-
erfusion therapy. RESULTS: We found 2333 (91%) pts were
admitted within 12 hours of onset of symptoms, where 49% had
primary PCI, 16% received thrombolytics, 15% received throm-
bolytics and PCI, 8% had PCI outside the 12 hours reperfusion
window, 9% didn’t receive PCI neither thrombolytics, 2% had
CABG: We report data from 393 patients who didn’t receive
reperfusion therapy and accounts for patients not receiving
primary PCI or thrombolytics: 66% had dyslipidaemia, 63%
hypertension, 37% CHF, 30% diabetes, 19% age >80, 12%
stable angina and 11% with PAD. Also, it was noted that 40% of
these patients experienced delay in-hospital diagnosis, and thus
haven’t received reperfusion therapy within the 12 hours
window, 10% were contraindicated to thrombolytics, and 39%
were scheduled to receive revascularisation. In-hospital mortality
accounted for 14% of the total untreated population. CONCLU-
SION: This study concludes that 17% of STEMI patients admit-
ted to Cath Lab hospitals within 12 hours of onset of symptoms
in Europe don’t receive reperfusion therapy even when catheral-
ization facilities are available.
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OBJECTIVES: Different statin dose titration and treatment
switching strategies of atorvastatin, rosuvastatin, and simvasta-
tin were compared in the Swedish setting. The objective was to
ﬁnd the optimal treatment mix strategy (i.e. a mix that provides
the greatest beneﬁts in terms of cost (€ in 2008 value) per patient
treated to target (PTT)) in high-risk patients with elevated LDL-
cholesterol (LDL-C). METHODS: A decision-analytic model
with Monte Carlo simulation was developed to estimate the
expected net beneﬁts of different statin treatment mix strategies.
Since it has been demonstrated that the optimal option may not
always have the highest probability of being cost-effective for a
given value of cost-effectiveness threshold (l), a new approach,
named the optimal treatment mix chart (OTMC), was devel-
oped. The OTMC is based on cost-effectiveness acceptability
frontiers (CEAF). RESULTS: In the base case (LDL-
C = 4.42 mmol/l) and when l < €350/PTT, the optimal option
was to initiate treatment with simvastatin 10 mg and to titrate
dose up to the assumed maximum tolerated dose (40 mg) until
the treatment target (LDL-C  2.5 mmol/l) was reached. When
€350 < l < €775, the optimal option was to initiate a treatment
mix, where simvastatin was up-titrated to 40 mg and then
switched to a higher-potency statin (here rosuvastatin), when
needed. When l > 775€ the optimal option was to initiate a
treatment with simvastatin 20 mg and then directly switch to
rosuvastatin, when needed. CONCLUSIONS: The selection of
the optimum treatment mix is conditional on baseline assump-
tions. OTMC provides a natural and practical graphic tool for
presenting the optimal treatment mix at different l-values under
different baseline assumptions (e.g. different baseline LDL-C
levels). The majority of Swedish patients will, currently and in
real-life, not generally experience dose titration and/or change of
statin after treatment initiation. Therefore, rosuvastatin has a
central role in a treatment “mix” for high risk patients with the
LDL-C exceeding 4.2 mmol/l.
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OBJECTIVES: To contain health care expenditure, the Korean
National Health Insurance (NHI) sets reimbursement criteria for
lipid-lowering therapy that are quite strict. We assessed the
potential health and economic effects of relaxing the criteria for
lipid-lowering treatment in Korea to align with NCEP-ATPIII
recommendations. METHODS: A microsimulation Markov
model was constructed with yearly cycles and the health states
‘Alive without cardiovascular disease (CVD)’, ‘Alive with CVD’,
‘Dead from CVD’ and ‘Dead from non-CVD causes’. It was
populated with CVD-naïve subjects aged 55 years from the
nationally-representative 2005 Korean NHANES. Follow-up
until death or age 99 years was simulated. An Asian-speciﬁc risk
equation (Wu 2006) was applied to estimate cardiovascular risks.
Sex-and-age-speciﬁc mortality risks were drawn from national
health statistics. Decision analysis compared treatment according
to the two sets of criteria. Eligible patients were all prescribed
atorvastatin, the lipid-modifying efﬁcacy and costs of which were
drawn from a meta-analysis and current drug pricing schedules,
respectively. CVD cost estimates were provided by the Korean
Health Insurance Review and Assessment Services. A ﬁve percent
annual discount rate was applied. RESULTS: Nearly three times
more Koreans aged 55 years would quality for lipid-lowering
therapy if NCEP-ATPIII instead of NHI criteria were to be
applied (43.1% vs 15.0%). Compared to treatment under NHI
criteria, the treatment of 1000 Koreans aged 55 years under
NCEP-ATPIII criteria would lead to 38 less cardiovascular events
(447 vs 409) and 3195 more QALYs (10,843 vs 7648) over a
lifetime. There would be saving of 845 million KW in net costs
(9876 vs 10,721 million). CONCLUSIONS: Current criteria for
lipid-lowering therapy in Korea are conservative. If NCEP-
ATPIII criteria were to be adopted, as in many other countries,
signiﬁcantly more patients would qualify for treatment, but the
strategy would represent a more effective and cost-effective way
of preventing CVD.
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